Which has better valuation & earnings, PLSE or IRMD?

iRadimed has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulse Biosciences $350K 9,944.37 -$72.78M -$1.18 N/A iRadimed $83.81M 13.00 $22.48M $1.79 47.60

Is PLSE or IRMD more profitable?

iRadimed has a net margin of 26.70% compared to Pulse Biosciences' net margin of -6,755.78%. iRadimed's return on equity of 23.45% beat Pulse Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Pulse Biosciences -6,755.78% -94.42% -79.96% iRadimed 26.70% 23.45% 20.36%

Does the media favor PLSE or IRMD?

In the previous week, Pulse Biosciences and Pulse Biosciences both had 3 articles in the media. iRadimed's average media sentiment score of 1.04 beat Pulse Biosciences' score of 0.44 indicating that iRadimed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iRadimed 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IRMD or IRTC?

In the previous week, iRhythm Technologies had 4 more articles in the media than iRadimed. MarketBeat recorded 7 mentions for iRhythm Technologies and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.04 beat iRhythm Technologies' score of 0.15 indicating that iRadimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRhythm Technologies 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, TMDX or IRMD?

TransMedics Group has higher revenue and earnings than iRadimed. TransMedics Group is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $605.49M 4.44 $190.29M $3.89 19.99 iRadimed $83.81M 13.00 $22.48M $1.79 47.60

Does the media refer more to TMDX or IRMD?

In the previous week, TransMedics Group had 6 more articles in the media than iRadimed. MarketBeat recorded 9 mentions for TransMedics Group and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.04 beat TransMedics Group's score of 0.36 indicating that iRadimed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iRadimed 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, IRMD or ATRC?

iRadimed has higher earnings, but lower revenue than AtriCure. iRadimed is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 13.00 $22.48M $1.79 47.60 AtriCure $534.53M 5.16 -$11.45M $0.21 258.40

Is IRMD or ATRC more profitable?

iRadimed has a net margin of 26.70% compared to AtriCure's net margin of 1.85%. iRadimed's return on equity of 23.45% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets iRadimed 26.70% 23.45% 20.36% AtriCure 1.85% 2.34% 1.77%

Does the media favor IRMD or ATRC?

In the previous week, AtriCure had 3 more articles in the media than iRadimed. MarketBeat recorded 6 mentions for AtriCure and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.04 beat AtriCure's score of 0.61 indicating that iRadimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AtriCure 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BFLY or IRMD?

In the previous week, Butterfly Network had 4 more articles in the media than iRadimed. MarketBeat recorded 7 mentions for Butterfly Network and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.04 beat Butterfly Network's score of 0.87 indicating that iRadimed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Butterfly Network 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRadimed 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

iRadimed (IRMD) Competitors

$85.40 +0.10 (+0.12%)

Closing price 04:00 PM Eastern

Extended Trading

$85.30 -0.10 (-0.12%)

As of 07:30 PM Eastern

Compare

IRMD vs. PLSE, IRTC, TMDX, ATRC, and BFLY

Should you buy iRadimed stock or one of its competitors? iRadimed's main competitors and comparable companies include Pulse Biosciences (PLSE), iRhythm Technologies (IRTC), TransMedics Group (TMDX), AtriCure (ATRC), and Butterfly Network (BFLY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does iRadimed compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and iRadimed (NASDAQ:IRMD) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 92.3% of iRadimed shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 34.6% of iRadimed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

iRadimed has a net margin of 26.70% compared to Pulse Biosciences' net margin of -6,755.78%. iRadimed's return on equity of 23.45% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
iRadimed	26.70%	23.45%	20.36%

Pulse Biosciences has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, iRadimed has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

In the previous week, Pulse Biosciences and Pulse Biosciences both had 3 articles in the media. iRadimed's average media sentiment score of 1.04 beat Pulse Biosciences' score of 0.44 indicating that iRadimed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iRadimed	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pulse Biosciences presently has a consensus price target of $50.20, suggesting a potential upside of 2.12%. iRadimed has a consensus price target of $120.00, suggesting a potential upside of 40.83%. Given iRadimed's higher possible upside, analysts clearly believe iRadimed is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
iRadimed	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83

iRadimed has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	9,944.37	-$72.78M	-$1.18	N/A
iRadimed	$83.81M	13.00	$22.48M	$1.79	47.60

Summary

iRadimed beats Pulse Biosciences on 10 of the 15 factors compared between the two stocks.

How does iRadimed compare to iRhythm Technologies?

iRadimed (NASDAQ:IRMD) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

iRadimed has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

iRadimed has a net margin of 26.70% compared to iRhythm Technologies' net margin of -1.69%. iRadimed's return on equity of 23.45% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
iRhythm Technologies	-1.69%	10.11%	1.53%

iRadimed has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	13.00	$22.48M	$1.79	47.60
iRhythm Technologies	$747.14M	4.87	-$44.55M	-$0.43	N/A

In the previous week, iRhythm Technologies had 4 more articles in the media than iRadimed. MarketBeat recorded 7 mentions for iRhythm Technologies and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.04 beat iRhythm Technologies' score of 0.15 indicating that iRadimed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRhythm Technologies	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

92.3% of iRadimed shares are held by institutional investors. 34.6% of iRadimed shares are held by company insiders. Comparatively, 1.0% of iRhythm Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

iRadimed presently has a consensus price target of $120.00, suggesting a potential upside of 40.83%. iRhythm Technologies has a consensus price target of $179.93, suggesting a potential upside of 62.99%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, analysts clearly believe iRhythm Technologies is more favorable than iRadimed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

Summary

iRadimed beats iRhythm Technologies on 10 of the 17 factors compared between the two stocks.

How does iRadimed compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and iRadimed (NASDAQ:IRMD) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

TransMedics Group currently has a consensus price target of $121.10, indicating a potential upside of 55.73%. iRadimed has a consensus price target of $120.00, indicating a potential upside of 40.83%. Given TransMedics Group's higher possible upside, research analysts plainly believe TransMedics Group is more favorable than iRadimed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
iRadimed	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by insiders. Comparatively, 34.6% of iRadimed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, TransMedics Group had 6 more articles in the media than iRadimed. MarketBeat recorded 9 mentions for TransMedics Group and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.04 beat TransMedics Group's score of 0.36 indicating that iRadimed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iRadimed	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRadimed has a net margin of 26.70% compared to TransMedics Group's net margin of 22.69%. iRadimed's return on equity of 23.45% beat TransMedics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	22.69%	15.88%	5.95%
iRadimed	26.70%	23.45%	20.36%

TransMedics Group has a beta of 1.94, indicating that its share price is 94% more volatile than the broader market. Comparatively, iRadimed has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

TransMedics Group has higher revenue and earnings than iRadimed. TransMedics Group is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	4.44	$190.29M	$3.89	19.99
iRadimed	$83.81M	13.00	$22.48M	$1.79	47.60

Summary

iRadimed beats TransMedics Group on 9 of the 17 factors compared between the two stocks.

How does iRadimed compare to AtriCure?

iRadimed (NASDAQ:IRMD) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

iRadimed currently has a consensus price target of $120.00, suggesting a potential upside of 40.83%. AtriCure has a consensus price target of $53.30, suggesting a potential downside of 1.78%. Given iRadimed's stronger consensus rating and higher probable upside, equities research analysts plainly believe iRadimed is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75

iRadimed has higher earnings, but lower revenue than AtriCure. iRadimed is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	13.00	$22.48M	$1.79	47.60
AtriCure	$534.53M	5.16	-$11.45M	$0.21	258.40

iRadimed has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, AtriCure has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

iRadimed has a net margin of 26.70% compared to AtriCure's net margin of 1.85%. iRadimed's return on equity of 23.45% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
AtriCure	1.85%	2.34%	1.77%

In the previous week, AtriCure had 3 more articles in the media than iRadimed. MarketBeat recorded 6 mentions for AtriCure and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.04 beat AtriCure's score of 0.61 indicating that iRadimed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AtriCure	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.3% of iRadimed shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 34.6% of iRadimed shares are held by insiders. Comparatively, 4.0% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

iRadimed beats AtriCure on 10 of the 16 factors compared between the two stocks.

How does iRadimed compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and iRadimed (NASDAQ:IRMD) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Butterfly Network presently has a consensus price target of $8.54, indicating a potential downside of 3.10%. iRadimed has a consensus price target of $120.00, indicating a potential upside of 40.83%. Given iRadimed's stronger consensus rating and higher probable upside, analysts plainly believe iRadimed is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
iRadimed	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83

iRadimed has lower revenue, but higher earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	24.05	-$77.06M	-$0.29	N/A
iRadimed	$83.81M	13.00	$22.48M	$1.79	47.60

iRadimed has a net margin of 26.70% compared to Butterfly Network's net margin of -66.74%. iRadimed's return on equity of 23.45% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-66.74%	-33.99%	-22.96%
iRadimed	26.70%	23.45%	20.36%

37.9% of Butterfly Network shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 22.0% of Butterfly Network shares are owned by insiders. Comparatively, 34.6% of iRadimed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Butterfly Network had 4 more articles in the media than iRadimed. MarketBeat recorded 7 mentions for Butterfly Network and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.04 beat Butterfly Network's score of 0.87 indicating that iRadimed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRadimed	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Butterfly Network has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, iRadimed has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Summary

iRadimed beats Butterfly Network on 11 of the 16 factors compared between the two stocks.

Get iRadimed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRMD vs. The Competition

Export

Metric	iRadimed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.09B	$5.48B	$7.14B	$13.10B
Dividend Yield	0.93%	1.81%	2.54%	16.76%
P/E Ratio	47.71	24.55	273.67	26.04
Price / Sales	12.65	67.76	611.82	91.49
Price / Cash	45.89	32.43	77.60	51.75
Price / Book	11.48	5.68	10.92	6.30
Net Income	$22.48M	$152.11M	$3.50B	$361.43M
7 Day Performance	-0.42%	-2.01%	-2.11%	-1.67%
1 Month Performance	-0.89%	-5.42%	-6.34%	-3.94%
1 Year Performance	20.15%	2.75%	8.81%	2.77%

iRadimed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRMD iRadimed	3.1555 of 5 stars	$85.40 +0.1%	$120.00 +40.5%	+21.1%	$1.09B	$86.34M	47.71	166
PLSE Pulse Biosciences	2.2061 of 5 stars	$53.42 +0.2%	$45.25 -15.3%	+175.0%	$3.78B	$350K	N/A	116
IRTC iRhythm Technologies	3.4346 of 5 stars	$110.09 -0.3%	$179.93 +63.4%	-33.7%	$3.63B	$747.14M	N/A	2,400	News Coverage
TMDX TransMedics Group	4.2954 of 5 stars	$88.11 +0.9%	$121.10 +37.4%	-31.6%	$3.04B	$605.49M	22.60	898
ATRC AtriCure	2.7511 of 5 stars	$58.89 +1.0%	$53.30 -9.5%	+56.6%	$3.00B	$534.53M	280.46	1,350	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRMD) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iRadimed (IRMD) Competitors

IRMD vs. PLSE, IRTC, TMDX, ATRC, and BFLY

How does iRadimed compare to Pulse Biosciences?

Summary

How does iRadimed compare to iRhythm Technologies?

Summary

How does iRadimed compare to TransMedics Group?

Summary

How does iRadimed compare to AtriCure?

Summary

How does iRadimed compare to Butterfly Network?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRMD vs. The Competition

iRadimed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iRadimed (IRMD) Competitors

IRMD vs. PLSE, IRTC, TMDX, ATRC, and BFLY

How does iRadimed compare to Pulse Biosciences?

Do insiders and institutionals have more ownership in PLSE or IRMD?

Is PLSE or IRMD more profitable?

Which has more volatility & risk, PLSE or IRMD?

Does the media favor PLSE or IRMD?

Do analysts rate PLSE or IRMD?

Which has better valuation & earnings, PLSE or IRMD?

Summary

How does iRadimed compare to iRhythm Technologies?

Which has more volatility and risk, IRMD or IRTC?

Is IRMD or IRTC more profitable?

Which has stronger earnings and valuation, IRMD or IRTC?

Does the media refer more to IRMD or IRTC?

Do insiders & institutionals have more ownership in IRMD or IRTC?

Do analysts recommend IRMD or IRTC?

Summary

How does iRadimed compare to TransMedics Group?

Do analysts recommend TMDX or IRMD?

Do institutionals & insiders have more ownership in TMDX or IRMD?

Does the media refer more to TMDX or IRMD?

Is TMDX or IRMD more profitable?

Which has more risk & volatility, TMDX or IRMD?

Which has better earnings and valuation, TMDX or IRMD?

Summary

How does iRadimed compare to AtriCure?

Do analysts prefer IRMD or ATRC?

Which has preferable valuation & earnings, IRMD or ATRC?

Which has more risk & volatility, IRMD or ATRC?

Is IRMD or ATRC more profitable?

Does the media favor IRMD or ATRC?

Do institutionals & insiders hold more shares of IRMD or ATRC?

Summary

How does iRadimed compare to Butterfly Network?

Do analysts rate BFLY or IRMD?

Which has preferable valuation & earnings, BFLY or IRMD?

Is BFLY or IRMD more profitable?

Do insiders and institutionals believe in BFLY or IRMD?

Does the media favor BFLY or IRMD?

Which has more risk and volatility, BFLY or IRMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRMD vs. The Competition

iRadimed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools